OBJECTIVE: To estimate the global prevalence and incidence of herpes simplex virus type 2 (HSV-2) infection in 2003. METHODS: A systematic review was undertaken of published seroprevalence surveys describing the prevalence or incidence of HSV-2 by age and gender. For each of 12 regions, pooled prevalence values by age and gender were generated in a random-effect model. HSV-2 incidence was then estimated from these pooled values using a constant-incidence model. Values of the HSV-2 seroprevalence from the model fits were applied to the total population to estimate the numbers of people infected. FINDINGS: The total number of people aged 15-49 years who were living with HSV-2 infection worldwide in 2003 is estimated to be 536 million, while the total number of people who were newly infected with HSV-2 in 2003 is estimated to be 23.6 million. While the estimates are limited by poor availability of data, general trends are evident. For example, more women than men were infected, and the number infected increased with age. Although prevalence varied substantially by region, predicted prevalence was mostly higher in developing regions than developed regions. CONCLUSION: The prevalence of HSV-2 is relatively easy to measure since infection is lifelong and has a specific serological test. The burden of disease is less easy to quantify. Despite the often sparse data on which these estimates are based, it is clear that HSV-2 infection is widespread. The dramatic differences in prevalence between regions are worthy of further exploration.
OBJECTIVE: To estimate the global prevalence and incidence of herpes simplex virus type 2 (HSV-2) infection in 2003. METHODS: A systematic review was undertaken of published seroprevalence surveys describing the prevalence or incidence of HSV-2 by age and gender. For each of 12 regions, pooled prevalence values by age and gender were generated in a random-effect model. HSV-2 incidence was then estimated from these pooled values using a constant-incidence model. Values of the HSV-2 seroprevalence from the model fits were applied to the total population to estimate the numbers of people infected. FINDINGS: The total number of people aged 15-49 years who were living with HSV-2 infection worldwide in 2003 is estimated to be 536 million, while the total number of people who were newly infected with HSV-2 in 2003 is estimated to be 23.6 million. While the estimates are limited by poor availability of data, general trends are evident. For example, more women than men were infected, and the number infected increased with age. Although prevalence varied substantially by region, predicted prevalence was mostly higher in developing regions than developed regions. CONCLUSION: The prevalence of HSV-2 is relatively easy to measure since infection is lifelong and has a specific serological test. The burden of disease is less easy to quantify. Despite the often sparse data on which these estimates are based, it is clear that HSV-2 infection is widespread. The dramatic differences in prevalence between regions are worthy of further exploration.
Authors: Anna Glasier; A Metin Gülmezoglu; George P Schmid; Claudia Garcia Moreno; Paul F A Van Look Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: Audrey E Pettifor; Ariane van der Straten; Megan S Dunbar; Stephen C Shiboski; Nancy S Padian Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Paul K Drain; Jennifer S Smith; James P Hughes; Daniel T Halperin; King K Holmes Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: David Serwadda; Ronald H Gray; Nelson K Sewankambo; Fred Wabwire-Mangen; Michael Z Chen; Thomas C Quinn; Tom Lutalo; Noah Kiwanuka; Godfrey Kigozi; Fred Nalugoda; Mary P Meehan; Rhoda Ashley Morrow; Maria J Wawer Journal: J Infect Dis Date: 2003-10-28 Impact factor: 5.226
Authors: R G Pebody; N Andrews; D Brown; R Gopal; H De Melker; G François; N Gatcheva; W Hellenbrand; S Jokinen; I Klavs; M Kojouharova; T Kortbeek; B Kriz; K Prosenc; K Roubalova; P Teocharov; W Thierfelder; M Valle; P Van Damme; R Vranckx Journal: Sex Transm Infect Date: 2004-06 Impact factor: 3.519
Authors: Edith Nakku-Joloba; Fred Kambugu; Julius Wasubire; Joshua Kimeze; Robert Salata; Jeffrey M Albert; Alfred Rimm; Christopher Whalen Journal: Afr Health Sci Date: 2014-12 Impact factor: 0.927
Authors: Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman Journal: J Virol Date: 2013-11-27 Impact factor: 5.103
Authors: Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen Journal: Antimicrob Agents Chemother Date: 2013-11-11 Impact factor: 5.191
Authors: Christine Johnston; Jia Zhu; Lichen Jing; Kerry J Laing; Christopher M McClurkan; Alexis Klock; Kurt Diem; Lei Jin; Jeffrey Stanaway; Elizabeth Tronstein; William W Kwok; Meei-Li Huang; Stacy Selke; Youyi Fong; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: J Virol Date: 2014-02-19 Impact factor: 5.103
Authors: Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman Journal: Sci Immunol Date: 2019-09-20